RxDoctor Payments Data

Anit Patel, MD

Internal Medicine · Fairfield, CANPI 1982646154

Payments from drug & device makers

$5,918in general payments, 2019–2025

Across 62 payments — averaging $95.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • Boehringer Ingelheim$1K
  • Amgen$574
  • GSK$428
  • Harmony Biosciences LLC$299
  • Actelion Pharmaceuticals US, Inc.$296
  • plus $826 from 8 others

What the payments were for

  • Consulting fees$1,30022%
  • Travel & lodging$1,29422%
  • Food & beverage$2,99951%
  • Education$3255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,918 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$260,012
Medicare patients
1,200
Services billed
4,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate20$249,303
Spiriva RespimatTiotropium Bromide188$156,414
Stiolto RespimatTiotropium Br/Olodaterol Hcl118$73,263
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$61,284
Incruse ElliptaUmeclidinium Bromide98$56,817
Spiriva HandihalerTiotropium Bromide34$37,995
Arnuity ElliptaFluticasone Furoate95$37,114
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$33,781
Breo ElliptaFluticasone/Vilanterol54$29,243
SymbicortBudesonide/Formoterol Fumarate53$18,867
Tiotropium Bromide12$13,124
Atrovent HfaIpratropium Bromide22$13,030
Advair HfaFluticasone Propion/Salmeterol28$12,606
Wixela InhubFluticasone Propion/Salmeterol70$12,066
DuleraMometasone/Formoterol16$10,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,479$478,980326 claims
GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta, Breo Ellipta$428$218,239390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →